Derek M. Meisner - 06 Sep 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Chief Legal Office & Corp Sec
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
06 Sep 2022
Net transactions value
$0
Form type
4
Filing time
07 Sep 2022, 16:31:41 UTC
Previous filing
19 Aug 2022
Next filing
18 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +225,000 $0.000000 225,000 06 Sep 2022 Common Stock 225,000 $6.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on September 6, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.